Insulin glargine (Toujeo) vs insulin icodec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin glargine (Toujeo)
Marketed by Sanofi
NCT01499082 · Phase 3 · completed
The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.
Reported efficacy
Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)
Result source: NCT01499082
insulin icodec · Awiqli
Marketed by Novo Nordisk
NCT04760626 · Phase 3 · completed
The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.
Next expected readout: October 2027 · NCT07747402 (registry estimate)
Reported efficacy
Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)
Result source: NCT06340854
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin glargine (Toujeo) | insulin icodec |
|---|---|---|
| HbA1c, change | —Not reported | -1.7% vs -1.3%vs Once Daily Basal Insulin AnalogueNCT0476062611 other results
|
| Body weight, change (kg) | —Not reported | 2.3 vs 1.8vs Insulin GlargineNCT0446088510 other results
|
| HbA1c below 7% | —Not reported | —Not posted · NCT05013229 |
| Fasting plasma glucose, change | —Not reported | -3.4 vs -3.3vs Insulin GlargineNCT044608859 other results
|
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05013229 |
HbA1c, change
- Insulin glargine (Toujeo)
- —Not reported
- insulin icodec
- -1.7% vs -1.3%vs Once Daily Basal Insulin AnalogueNCT04760626
11 other results
- -1.6% vs -1.4% NCT04460885
- -0.8% vs -0.6% NCT06340854
- -1.6% vs -1.4% NCT04795531
- -0.9% vs -0.7% NCT04770532
- -1.2% vs -1.2% NCT04880850
- -1.3% vs -1.1% NCT03751657
- -0.5% vs -0.5% NCT03922750
- -0.8% vs -0.5% NCT03922750
- -1% vs -1.0% NCT03951805
- -1.2% vs -1.0% NCT03951805
- -1.4% vs -1.0% NCT03951805
Body weight, change (kg)
- Insulin glargine (Toujeo)
- —Not reported
- insulin icodec
- 2.3 vs 1.8vs Insulin GlargineNCT04460885
10 other results
- 2.0 vs 0.6 NCT06340854
- 2.8 vs 2.3 NCT04795531
- 1.4 vs -0.3 NCT04770532
- 2.7 vs 2.2 NCT04880850
- 1.5 vs 1.6 NCT03751657
- 1.3 vs 0.1 NCT03922750
- 0.6 vs 0.1 NCT03922750
- 0.9 vs 0.6 NCT03951805
- 1.1 vs 0.6 NCT03951805
- 1.3 vs 0.6 NCT03951805
HbA1c below 7%
- Insulin glargine (Toujeo)
- —Not reported
- insulin icodec
- —Not posted · NCT05013229
Fasting plasma glucose, change
- Insulin glargine (Toujeo)
- —Not reported
- insulin icodec
- -3.4 vs -3.3vs Insulin GlargineNCT04460885
9 other results
- -3.0 vs -3.0 NCT04795531
- -1.6 vs -1.6 NCT04770532
- -1.8 vs -1.6 NCT04880850
- -3.2 vs -3.0 NCT03751657
- -0.8 vs -0.6 NCT03922750
- -0.7 vs -0.6 NCT03922750
- -2.2 vs -2.3 NCT03951805
- -2.4 vs -2.3 NCT03951805
- -3.0 vs -2.3 NCT03951805
3-point MACE (% with event)
- Insulin glargine (Toujeo)
- —Not reported
- insulin icodec
- —Not posted · NCT05013229
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Insulin glargine (Toujeo): 8 of 8 rows · insulin icodec: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin glargine (Toujeo) Rows use multiple source trials | insulin icodec Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -2.66 mmol/L @ 52wk*a,b,c NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48 mg/dL as posted | -1.29 mmol/L @ 52wka,b,c NCT05813912 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.29% (n=1651) @ 52wka,b,c NCT02451137 · Phase 4 · registry result, not featured evidence | -1.23% (n=91) @ 52wka,b,c NCT05813912 · Phase 3 · registry result, not featured evidence · combination |
| Time in Range absolute value · percentage points | 50.3% (n=92) vs 54.9% (n=84) Glargine U100 @ 12wka,b,c,d NCT03013985 · Phase 4 · registry result, not featured evidence | 71.94% (n=439) vs 66.9% (n=440) Insulin Glargine @ 52wka,b,c,d NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Weight absolute change · kg No placebo or comparator arm | 1.51 kg @ 52wka,b,c NCT02451137 · Phase 4 · registry result, not featured evidence | -3.85 kg @ 52wka,b,c NCT05813912 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 14.8%e NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result14.9% NCT02451137 · Phase 4 · registry result, not featured evidence | 8.3%f NCT04760626 · Phase 3 show 14 more results3.7% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 2% NCT04795531 · Phase 3 1.1% NCT04770532 · Phase 3 5.5% NCT04880850 · Phase 3 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 2% NCT05823948 · Phase 3 · registry result, not featured evidence 1.9%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence 2.4% NCT03751657 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —e NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result2.6% NCT02451137 · Phase 4 · registry result, not featured evidence | —f NCT04760626 · Phase 3 show 14 more results— NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT04795531 · Phase 3 — NCT04770532 · Phase 3 — NCT04880850 · Phase 3 —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination — NCT05823948 · Phase 3 · registry result, not featured evidence 1.9%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence — NCT03751657 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 19.4%e NCT03013985 · Phase 4 · registry result, not featured evidence show 1 more result9.8% NCT02451137 · Phase 4 · registry result, not featured evidence | 8.3%f NCT04760626 · Phase 3 show 14 more results13% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.8% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.1% NCT04795531 · Phase 3 8.4% NCT04770532 · Phase 3 7.6% NCT04880850 · Phase 3 —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.9% NCT05823948 · Phase 3 · registry result, not featured evidence 3.7%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence 1.6% NCT03751657 · Phase 2 · registry result, not featured evidence 5.9%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | e trauma 3.7% cough 0.9% gastroparesis 0.9% NCT03013985 · Phase 4 · registry result, not featured evidence | show 13 more resultscovid-19 17.7% back pain 8.1% diarrhoea 7.9% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 nasopharyngitis 13.6% diarrhoea 5.3% diabetic retinopathy 2.9% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.7% covid-19 9.8% back pain 7.8% NCT05823948 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.8% medical device site haemorrhage 9.3% headache 5.6% NCT03922750 · Phase 2 · registry result, not featured evidence nasopharyngitis 14% hypertension 6% influenza 6% NCT03922750 · Phase 2 · registry result, not featured evidence headache 11.2% nasopharyngitis 8% upper respiratory tract infection 5.6% NCT03751657 · Phase 2 · registry result, not featured evidence back pain 9.8% nasopharyngitis 9.8% headache 0% NCT03951805 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.7% headache 5.9% back pain 3.9% NCT03951805 · Phase 2 · registry result, not featured evidence headache 9.6% nasopharyngitis 3.8% back pain 1.9% NCT03951805 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 12 weeks.
- ePopulation comparability has not been reviewed for these studies.
- fPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin glargine (Toujeo)
show 6 more results
show 1 more result
insulin icodec
show 11 more results
show 9 more results
show 10 more results
show 2 more results
show 3 more results
show 3 more results
show 3 more results
show 5 more results
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Toujeo)'s landscape · insulin icodec's landscape